Fig. 6: Tumors exhibit a gene expression signature of enhanced immune responses upon agonist combination therapy. | Nature Immunology

Fig. 6: Tumors exhibit a gene expression signature of enhanced immune responses upon agonist combination therapy.

From: Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity

Fig. 6

Bulk RNA-seq was conducted using total RNA isolated from KPC tumors on the day of tumor resection (day 14), and the data were processed by DEseq2. a, Heat map showing differential gene expression between the untreated control and agonist-treated groups. b, Expression levels of genes related to inflammation, innate immunity and adaptive immunity in tumors of different treatment groups. One experiment. N = 8 tumors were examined representing biological replicates for each group. Data are presented as the mean ± s.e.m. c, Gene-set enrichment analysis (GSEA) was performed using the RNA-seq data. Each treatment group was compared to the control group. Normalized enrichment score (NES) for each Gene Ontology term is shown. d, Expression of mouse IgG heavy chain detected in tumors. Eight tumors were examined for each group. In these bulk RNA-seq analyses, individual tumors were sequenced without pooling, and the results from two independent experiments were combined. A total of eight tumors were examined per group. e, Expression of IgG heavy chain detected in TLS-rich and TLS-free human cancer. Pancreatic ductal adenocarcinomas were categorized into TLS-free and TLS-rich tumors, and the expression of class-switched IgG heavy chain was determined by RNA-seq of these tumors. N = 6 tumors from individuals with cancer were examined for each group. f, A similar RNA-seq analysis of IgG expression in human breast adenocarcinomas categorized into TLS-free and TLS-rich tumors. N = 8 individuals with cancer were examined for each group. FDR, false discovery rate.

Back to article page